Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CIPLA.NSthis companyCipla Limited	₹1,403.80	25.49×	2.87×	3.51×	15.19×	112.4%	42.7%	16.7%	13.8%	11.3%	9.8%	2.6%	0.02×	-0.06×	86.67×	3.44×	1.3%	4	9.92	4	A-
APLLTD.NSAlembic Pharmaceuticals Limited	₹1,017.30	19.32×	2.3×	1.77×	12.9×	3.1%	45.1%	10.9%	9.2%	11.9%	10.4%	2.0%	0.25×	1.11×	8.54×	1.76×	1.7%	4	—	2	B-
AUROPHARMA.NSAurobindo Pharma Limited	₹1,855.30	21.62×	2×	2.25×	10.17×	130.3%	39.2%	15.1%	10.4%	9.2%	7.3%	3.7%	0.21×	-0.25×	13.22×	1.81×	0.3%	5	—	2	B-
DRREDDY.NSDr. Reddy's Laboratories Limited	₹1,385.00	24.38×	2.77×	3.11×	14.13×	25.1%	52.8%	13.8%	12.8%	11.4%	7.5%	2.9%	0.24×	0.94×	12.42×	1.8×	0.6%	7	5.66	3	B+
GLENMARK.NSGlenmark Pharmaceuticals Limited	₹2,671.10	44.17×	5.72×	3.54×	21.53×	-44.3%	47.6%	23.5%	8.0%	13.0%	20.1%	3.2%	0.06×	-0.21×	19.16×	1.77×	0.2%	7	6.63	1	D+
IPCALAB.NSIpca Laboratories Limited	₹1,959.70	35.6×	5.04×	4.21×	20.83×	-60.6%	64.1%	24.2%	11.8%	14.2%	16.5%	1.2%	0.1×	0.12×	30.7×	2.76×	0.1%	6	12.14	2	C
Peer median	—	24.38×	2.77×	3.11×	14.13×	3.1%	47.6%	15.1%	10.4%	11.9%	10.4%	2.9%	0.21×	0.12×	13.22×	1.8×	0.3%	6	6.63	2	—